Please assess the completion status of the following clinical trial:

Trial Title: Study of Low Level Laser Therapy and Tinnitus Relief

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Total score on the Tinnitus Handicap Inventory (THI) of at least 20.~* Tinnitus is on-going; present for more than 50% of the time over the past 6 months.~* Subject has been previously evaluated by a qualified health care professional for tinnitus and received a diagnosis of etiology of tinnitus related to hearing impairment and/or noise exposure and/or unknown.~* Any existing hearing loss stable over the past 12 months.~* Willingness to abstain from partaking in other, non-study procedures indicated to lessen tinnitus and/or its perception, with the exclusion of wearing hearing aids for those subjects who enter the study using hearing aids, throughout the course of study participation.~* Willing and able to refrain from engaging in activities or work involving loud noise exposure, such as hunting, rock concerts and work situations that involve working around loud machinery, construction sites, etc., throughout the course of study participation.~* 18 years or older.~* Male or female.~* English as primary spoken language.~Exclusion Criteria:~* Presence of any of the following or in the subject's medical history:~* physical trauma or surgery to the head or neck~* uncontrolled hypertension~* current or prior surgically removed acoustic neuroma middle ear infection/active drainage from the ear and/or history of either within the previous 90 days~* impacted cerumen~* thyroid disease~* vascular disorders~* Temporomandibular Joint Disorder (TMJD)~* nutritional deficiency~* aneurysm~* multiple sclerosis~* Episodic or infrequent tinnitus~* Somatic or pulsatile tinnitus~* Prior history of sudden hearing loss and/or fluctuating hearing levels .~* Consistent use of any of the following drugs within the past 30 days:~NSAIDS; aspirin and other salicylates; Lasix and ther loopdiuretics; mycin antibiotics such as vancomycin; quinine and related drugs; Chemotherapy agents such as cis-platin.~* Acute or chronic vertigo/dizziness.~* Prior diagnosis of central auditory processing disorder.~* Ménière's disease.~* Tympanic membrane perforation or tubes.~* Prior stapedectomy~* Prior mastoidectomy.~* Otosclerosis.~* Otosyphilis.~* Labyrinthitis.~* Auditory nerve damage.~* Stapedius myoclonus syndrome.~* Brain and/or brainstem injury.~* Cochlear implant.~* Photosensitivity disorder.~* Active/open infection, wound or other external trauma to the areas to be treated with the Hearing Laser.~* Pregnant or lactating.~* Serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in past two years.~* Developmental disability or cognitive impairment that would make it difficult for the subject to partake in the clinical study, including adequate comprehension of the informed consent form and ability to record the necessary measurements.~* History of drug or alcohol abuse.~* Involvement in litigation and/or a worker's compensation claim and/or receiving disability benefits related to tinnitus and/or hearing loss.~* Participation in research in the past 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Erchonia Hearing Lasers #1 & #2 (Type: ACTIVE_COMPARATOR): Erchonia Hearing Laser #1 is a dual laser system composed of a pulsed red 7.5 milliwatts (mW) laser of 635 nm +/- 5 nm and a pulsed green 7.5 mW laser of 532 nm, both lasers in simultaneous operation when the laser is activated.~Erchonia Hearing Laser #2 is a single diode laser that in pulsed mode emits 4.9 mW of red 635 nm +/- 5 nm light.
- Placebo Lasers (Type: PLACEBO_COMPARATOR): Inactive lasers that do not emit any therapeutic light.

Based on this trial design, predict the completion outcome and termination type (if applicable).